1. Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers
- Author
-
Herta Flor, Oliver Grimm, Cathrin Rohleder, Dagmar Koethe, F Markus Leweke, Timothy A Couttas, Carola Boost, Franziska Pahlisch, Eliska B Sykorova, Juliane K Mueller, Beverly Jieu, Judith E Leweke, Inga Dammann, Anna E Hoffmann, Martin Loeffler, Frank Enning, and Andreas Meyer-Lindenberg
- Subjects
Psychiatry ,RC435-571 - Abstract
Background The mental health benefits of cannabidiol (CBD) are promising but can be inconsistent, in part due to challenges in defining an individual’s effective dosage. In schizophrenia, alterations in anandamide (AEA) concentrations, an endocannabinoid (eCB) agonist of the eCB system, reflect positively on treatment with CBD. Here, we expanded this assessment to include eCBs alongside AEA congeners, comparing phytocannabinoids and dosage in a clinical setting.Methods Liquid chromatography-tandem mass spectrometry quantified changes in serum levels of AEA, 2-arachidonoylglycerol (2-AG), alongside AEA-related compounds oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), which were attained from two independent, parallel-designed, clinical trials investigating single, oral CBD (600 or 800 mg), delta-9-tetrahydrocannabinol (Δ9-THC, 10 or 20 mg) and combination administration (CBD|800 mg+Δ9-THC|20 mg) in healthy volunteers (HVs, n=75). Concentrations were measured at baseline (t=0), 65 and 160 min post administration.Results CBD-led increases in AEA (1.6-fold), OEA and PEA (1.4-fold) were observed following a single 800 mg (pcorr
- Published
- 2024
- Full Text
- View/download PDF